Get the Stockscreener App
6.94
1.98%
-0.14
Sage Therapeutics Inc stock is traded at $6.94, with a volume of 2.06M.
It is down -1.98% in the last 24 hours and up +23.71% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$7.08
Open:
$7.07
24h Volume:
2.06M
Relative Volume:
1.48
Market Cap:
$424.54M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-0.8272
EPS:
-8.39
Net Cash Flow:
$-424.74M
1W Performance:
-6.72%
1M Performance:
+23.71%
6M Performance:
-43.53%
1Y Performance:
-73.32%
1-Day Range:
$6.71
$7.105
1-Week Range:
$6.71
$7.61
52-Week Range:
$4.62
$27.68
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare SAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
6.94 | 424.54M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-04-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-29-24 | Initiated | Citigroup | Sell |
| May-29-24 | Initiated | Robert W. Baird | Neutral |
| Apr-17-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Sage sues Biogen after unsolicited takeover bid - pharmaphorum
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid - MSN
Sage sues Biogen in wake of $469M buyout offer: report (BIIB:NASDAQ) - Seeking Alpha
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1) - Bloomberg Law
BB Biotech AG Significantly Reduces Stake in Sage Therapeutics Inc - GuruFocus.com
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Biogen Offers to Buy Remaining Stake in Sage Therapeutics - MSN
Sage Therapeutics, Inc. (NASDAQ:SAGE) Short Interest Down 24.6% in December - MarketBeat
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders - Seeking Alpha
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen - MSN
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last? - MSN
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In - MSN
Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist - Yahoo Finance
Biogen proposes acquisition of partner Sage Therapeutics - MSN
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts - Benzinga
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge - Benzinga
Sage Therapeutics shares surge on unsolicited takeover bid from Biogen - Proactive Investors USA
Sage Therapeutics Stock Headed for Best Day in 5 Years - Schaeffers Research
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday - Benzinga
Sage Therapeutics Jumps on Biogen’s $469 Million Offer - Bloomberg
Biogen CEO confirms he’s shopping for biotechs: ‘We will be doing deals’ - The Boston Globe
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? - Yahoo Finance
Biogen Submits Offer to Buy Embattled Partner Sage - BioSpace
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
SAGE Therapeutics Outlines 2025 Strategy and Acquisition Proposal - TipRanks
Sage Therapeutics shares spike after Biogen offers to buy remaining stake - Investing.com
SAGE Therapeutics (SAGE) Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (BIIB) (earlier) - StreetInsider.com
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - BioSpace
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Sage Therapeutics Unveils 2025 Strategy, Doubles Down on Postpartum Depression Drug ZURZUVAE - StockTitan
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Sage Therapeutics confirms $7.22 per share acquisition proposal from Biogen - MSN
Sage confirms unsolicited takeover bid from Biogen - The Pharma Letter
(SAGE) Investment Report - Stock Traders Daily
Sage confirms Biogen’s bid to acquire remaining stake - MSN
Sage stock gains on Biogen’s buyout offer (SAGE:NASDAQ) - Seeking Alpha
Biogen Moves to Acquire Sage Therapeutics Amid Pharmaceutical Market ShiftsNews and Statistics - IndexBox, Inc.
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - AccessWire
Deal Or No Deal? Sage Therapeutics Soars On Acquisition Proposal From Biogen - RTTNews
Biogen offers to buy out Sage Therapeutics - The Business Journals
Sage Therapeutics Receives Surprise $7.22 Per Share Acquisition Offer from Biogen - StockTitan
Biogen proposes to buy remaining stake in Sage in $442 million deal - Reuters
Biogen moves to acquire struggling partner Sage - FirstWord Pharma
Sage Therapeutics (NASDAQ:SAGE) Stock Passes Below 200 Day Moving AverageHere's Why - MarketBeat
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):